JP2022542472A5 - - Google Patents

Info

Publication number
JP2022542472A5
JP2022542472A5 JP2022506612A JP2022506612A JP2022542472A5 JP 2022542472 A5 JP2022542472 A5 JP 2022542472A5 JP 2022506612 A JP2022506612 A JP 2022506612A JP 2022506612 A JP2022506612 A JP 2022506612A JP 2022542472 A5 JP2022542472 A5 JP 2022542472A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
hvr
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542472A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044583 external-priority patent/WO2021026021A1/en
Publication of JP2022542472A publication Critical patent/JP2022542472A/ja
Publication of JP2022542472A5 publication Critical patent/JP2022542472A5/ja
Pending legal-status Critical Current

Links

JP2022506612A 2019-08-02 2020-07-31 抗siglec-8抗体および副腎皮質ステロイド薬を投与する方法 Pending JP2022542472A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882330P 2019-08-02 2019-08-02
US62/882,330 2019-08-02
PCT/US2020/044583 WO2021026021A1 (en) 2019-08-02 2020-07-31 Methods of administering anti-siglec-8 antibodies and corticosteroids

Publications (2)

Publication Number Publication Date
JP2022542472A JP2022542472A (ja) 2022-10-03
JP2022542472A5 true JP2022542472A5 (https=) 2023-07-31

Family

ID=74504001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506612A Pending JP2022542472A (ja) 2019-08-02 2020-07-31 抗siglec-8抗体および副腎皮質ステロイド薬を投与する方法

Country Status (11)

Country Link
US (1) US20220257758A1 (https=)
EP (1) EP4007606A4 (https=)
JP (1) JP2022542472A (https=)
KR (1) KR20220044203A (https=)
CN (1) CN114466664A (https=)
AU (1) AU2020325097A1 (https=)
BR (1) BR112022001395A2 (https=)
CA (1) CA3149484A1 (https=)
IL (1) IL290111A (https=)
MX (1) MX2022001403A (https=)
WO (1) WO2021026021A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270304B2 (en) * 2017-05-05 2024-07-01 Allakos Inc Methods and preparations for the treatment of inflammatory disorders in the digestive system
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
WO2024043940A1 (en) * 2022-08-25 2024-02-29 Allakos Inc. Methods and compositions for treating atopic dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ720769A (en) * 2013-12-09 2022-10-28 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
JP2020504135A (ja) * 2017-01-06 2020-02-06 アラコス インコーポレイテッド 慢性閉塞性肺障害を処置するための方法および組成物
EP3618868A4 (en) * 2017-05-05 2021-02-24 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
IL270304B2 (en) * 2017-05-05 2024-07-01 Allakos Inc Methods and preparations for the treatment of inflammatory disorders in the digestive system

Similar Documents

Publication Publication Date Title
JP2022542472A5 (https=)
JP2023517236A5 (https=)
JP5604311B2 (ja) 疾患治療剤
EP2262838B1 (en) Agent for treating disease
JP2020193218A (ja) Il−4r阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
JP2010526088A (ja) 抗il−5抗体を投与するための方法
CN102027017A (zh) 一种治疗疾病的试剂
JP2022520105A5 (https=)
JP2022532356A5 (https=)
JP2017507945A5 (https=)
JP2025122028A (ja) Il-33アンタゴニストを投与することにより喘息を治療するまたは予防するための方法
JP2018533569A5 (https=)
JP2024534602A5 (https=)
AU2019269131B2 (en) Antibodies against LIF and dosage forms thereof
JP2012504110A (ja) 疾患治療組成物
JP2020504135A5 (https=)
JP2024527401A5 (https=)
JP2022529929A5 (https=)
JP2023546503A5 (https=)
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
JP2024540435A5 (https=)
JP2021523117A5 (https=)
JP2023506779A5 (https=)
JP7093940B2 (ja) 全身性強皮症治療用医薬組成物
JP2022553378A5 (https=)